Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Progenics Pharmaceuticals Inc. PGNX

Healthcare Biotechnology
"Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate... see more

Recent & Breaking News (NDAQ:PGNX)

Progenics Pharmaceuticals Sets Fourth Quarter and Year End 2014 Financial Results Call for March 16

GlobeNewswire March 9, 2015

Progenics Pharmaceuticals Announces Presentation at ENDO 2015

GlobeNewswire March 2, 2015

Progenics Pharmaceuticals Presents Positive Phase 2 Data for PSMA ADC in Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire February 26, 2015

Progenics Pharmaceuticals to Present Full Phase 2 Data for PSMA ADC at the 2015 ASCO GU Symposium

GlobeNewswire February 23, 2015

Progenics Pharmaceuticals to Present at the 2015 RBC Capital Markets' Healthcare Conference

GlobeNewswire February 17, 2015

Progenics Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference

GlobeNewswire February 3, 2015

Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA(TM) in Pheochromocytoma

GlobeNewswire January 23, 2015

Progenics Pharmaceuticals Announces Presentation at RSNA Annual Meeting

GlobeNewswire December 2, 2014

Progenics Pharmaceuticals to Participate in Upcoming Conferences

GlobeNewswire November 11, 2014

Progenics Pharmaceuticals Announces Third Quarter 2014 Financial Results

GlobeNewswire November 7, 2014

Progenics Pharmaceuticals Sets Third Quarter Financial Results Call for November 7

GlobeNewswire October 27, 2014

Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

GlobeNewswire October 20, 2014

Progenics Receives $40 Million Milestone Following FDA Approval of RELISTOR for OIC Patients With Chronic Non-Cancer Pain

GlobeNewswire October 6, 2014

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Business Wire September 29, 2014

Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma

GlobeNewswire September 22, 2014

FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain

Business Wire August 11, 2014

Progenics Pharmaceuticals Announces Second Quarter 2014 Financial Results

GlobeNewswire August 8, 2014

Progenics Pharmaceuticals Sets Second Quarter Financial Results Call for August 8

GlobeNewswire July 31, 2014

Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for Patients With Chronic Non-Cancer Pain

GlobeNewswire July 14, 2014

FDA Office of Drug Evaluation III Approves Salix's Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain

Business Wire July 14, 2014